<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02958059</url>
  </required_header>
  <id_info>
    <org_study_id>4-2015-0596</org_study_id>
    <nct_id>NCT02958059</nct_id>
  </id_info>
  <brief_title>Effectiveness of Prophylactic Antibiotics to Prevent Post Endoscopic Retrograde Cholangio Pancreatography Bacteremia in Biliary Obstruction Patient</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Endoscopic retrograde cholangio-pancreatography (ERCP) is advanced endoscopic technique that
      allows minimally invasive management of biliary and pancreatic disorders. However, the
      incidence of infectious complication of ERCP is considerable. Transient blood stream
      infection after ERCP has been reported in a high ratio, up to 27% and post-ERCP infection
      accounts for about 10% of the major complications associated with mortality.

      Although prophylactic use of antibiotics is generally not recommend in all cases, debates
      about the prophylactic use of antibiotics continues and prophylactic use of antibiotics is
      recommend in case of ERCP that incomplete biliary drainage is expected.

      In this study, researchers will use prophylactic antibiotics in patients with biliary
      obstruction who have high-risk of post-ERCP bacteremia. Antibiotics regimen is selected based
      on the data of our institution, and administered to patients before ERCP procedure.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2016</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of complication that related with infection.</measure>
    <time_frame>within 10 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of post-ERCP cholangitis</measure>
    <time_frame>within 10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade of post-ERCP infectious complication</measure>
    <time_frame>within 10 days</time_frame>
    <description>Grade of post-ERCP infectious complications based upon a consensus definition Mild : &gt;38°C for 24-48 hr / Moderate : Febrile or septic illness requiring more than 3 days of hospital treatment or endoscopic or percutaneous intervention / Severe : Septic shock or surgery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Biliary Obstructive Disease Such as Choledocholithiasis</condition>
  <condition>Benign Biliary Stricture</condition>
  <condition>Peri-ampullary Cancer</condition>
  <condition>Bile Duct Cancer Resectable</condition>
  <condition>Klatskin Tumor</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The intervention group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The comparator group</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pacetin® (cefoxitin)</intervention_name>
    <description>1~2g of Cefoxitin (2nd generation cephalosporin) is administered to patients 30 minutes Before ERCP procedure. Cefoxitin is mixed with 10ml of normal saline. Patients and caregivers can not distinguish antibiotics and placebo by naked eye.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Antibiotic prophylaxis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>10ml of normal saline is injected to patients as placebo. Patients and caregivers can not distinguish antibiotics and placebo by naked eye.</description>
    <arm_group_label>Comparator</arm_group_label>
    <other_name>normal saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with biliary obstructive disease (Benign or Malignant)

          -  19 year-old and older than 19 year-old

        Exclusion Criteria:

          -  Younger than 19 year-old

          -  Patients with leukocytosis (WBC ≥ 11,000/mm3)

          -  Body temperature ≥ 38 °C within 72 hours before ERCP

          -  History of antibiotics administration due to cholangitis, cholecystitis or sepsis
             within 72 hours before ERCP

          -  Pregnancy women

          -  Patients with allergy to beta-lactam
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Seung Min Bang, MD</last_name>
    <phone>+82-02-2228-1995</phone>
    <email>BANG7028@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yonsei university of medical center</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seung Min Bang, MD</last_name>
      <phone>+82 2 2228 1995</phone>
      <email>BANG7028@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 2016</study_first_submitted>
  <study_first_submitted_qc>November 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2016</study_first_posted>
  <last_update_submitted>January 1, 2018</last_update_submitted>
  <last_update_submitted_qc>January 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ERCP</keyword>
  <keyword>prophylaxis</keyword>
  <keyword>antibiotics</keyword>
  <keyword>infection</keyword>
  <keyword>cholangitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bile Duct Neoplasms</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
    <mesh_term>Choledocholithiasis</mesh_term>
    <mesh_term>Klatskin Tumor</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Cefoxitin</mesh_term>
    <mesh_term>Cefotaxime</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

